Últimas noticias sobre Datadog (NASDAQ:DDOG) Bolsa

Datadog

Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered via software as a service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of applications throughout their businesses.

Datadog Inc

<ul>
<li>Final 3-year outcome of Focal Ablation versus Radical Prostatectomy (FARP) Randomized Controlled Trial (RCT) presented at 120th AUA Annual Meeting on Sunday, April 27, 2025.</li>
<li>Study achieved its primary endpoint and demonstrated that the rate of treatment failure in the Focal Ablation (FA) group is non-inferior to that in the Radical Prostatectomy (RP) group at the final 36-month follow-up.</li>
</ul>
AUSTIN, Texas, April 29, 2025 - EDAP TMS SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>), the global leader in robotic energy-based therapies, announced the positive final results of the Focal Ablation Versus Radical Prostatectomy (FARP) Study, the first randomized controlled trial completed comparing ultrasound energy-based focal ablation versus Robotic Prostatectomy. The study achieved its primary endpoint and demonstrated that the rate of treatment failure in the Focal Ablation (FA) group is non-inferior to that in the Radical Prostatectomy (RP) group at the final 36-month follow-up.

News

EDAP

EDAP TMS Final Results Of FARP Study Achieves Primary Endpoint, Confirms Non-Inferiority Of Focal Ablation Vs. Radical Prostatectomy At 36-Month Follow-Up

D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) with a Buy and maintains $10 price target.

Price Target

Analyst Ratings

TVGN

D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Maintains $10 Price Target

Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) affirms FY2025 Adj EPS guidance from $3.75-$3.95 to $3.75-$3.95 vs $3.87 analyst estimate..

Guidance

Entergy Affirms FY2025 Adj EPS Guidance of $3.75-$3.95 vs $3.87 Est

Rosenblatt analyst Kevin Cassidy maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Buy and lowers the price target from $76 to $50.

Rosenblatt Maintains Buy on Western Digital, Lowers Price Target to $50

Data continue to validate the potential of MT1-MMP as a novel cancer target and further underscore the applicability of Bicycle&#xAE; Radioconjugates (BRC&#xAE;) for radiopharmaceutical imaging
Data are representative of 12 patients with various solid tumors imaged with an early BRC molecule targeting MT1-MMP
Initial human imaging data for second BRC molecule targeting EphA2 expected in 2H 2025
Company-sponsored radiopharmaceutical clinical trials planned for 2026
Bicycle Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle&#xAE;) technology, announced the presentation of additional human imaging data that validate the potential of MT1-MMP, a tumor antigen overexpressed in many cancers, as a novel target for cancer treatment and demonstrate the positive properties of Bicycle&#xAE; Radioconjugates (BRC&#xAE;) for radiopharmaceutical imaging. The data will be presented today during a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago.

BCYC

Bicycle Therapeutics Presents Addl Human Radiopharmaceutical Imaging Data For MT1-MMP At AACR Annual Meeting 2025

Rosenblatt analyst Barton Crockett initiates coverage on Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Buy rating and announces Price Target of $77.

Initiation

Rosenblatt Initiates Coverage On Trade Desk with Buy Rating, Announces Price Target of $77

Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination
Quanterix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>), The Spatial Biology Company&#xAE;, today announced an amendment to the terms of their previously announced merger agreement.
Under the amended terms, Quanterix will issue approximately 7.76 million shares of its common stock and pay $20 million in cash to Akoya shareholders. Each Akoya share will receive $0.38 per share in cash and 0.1461 shares of Quanterix common stock.
With the amended exchange ratio, Quanterix will issue over 9 million fewer shares than under the original deal terms. Quanterix shareholders will own approximately 84% of the combined company and Akoya shareholders will own approximately 16%.

AKYA

QTRX

Quanterix To Issue About 7.76M Shares, Pay $20M In Cash To Akoya Shareholders Under Amended Merger Terms

Rosenblatt analyst Barton Crockett initiates coverage on Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) with a Buy rating and announces Price Target of $15.

NEXN

Rosenblatt Initiates Coverage On Nexxen International with Buy Rating, Announces Price Target of $15

Daqo New Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.69) by 15.94 percent. This is a 245.45 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $123.91 million which missed the analyst consensus estimate of $182.08 million by 31.94 percent. This is a 70.16 percent decrease over sales of $415.31 million the same period last year.

Earnings

Earnings Misses

Daqo New Energy Q1 Adj. EPS $(0.80) Misses $(0.69) Estimate, Sales $123.91M Miss $182.08M Estimate

S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) raises FY2025 GAAP EPS guidance from $14.20-$14.45 to $14.60-$15.10 vs $14.17 analyst estimate. Lowers FY2025 sales outlook from $14.92 billion-$15.20 billion to $14.78 billion-$15.06 billion vs $14.99 billion estimate.

SPGI

S&P Global Raises FY2025 GAAP EPS Guidance from $14.20-$14.45 to $14.60-$15.10 vs $14.17 Est; Lowers FY2025 Sales Guidance from $14.92B-$15.20B to $14.78B-$15.06B vs $14.99B Est

Earnings Beats

NAUT

Nautilus Biotechnology Q1 EPS $(0.13) Beats $(0.16) Estimate, Cash Balance Of $192.8M

S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) widens FY2025 Adj EPS guidance from $17.00-$17.25 to $16.75-$17.25 vs $17.01 analyst estimate. Lowers FY2025 sales outlook from $14.92 billion-$15.20 billion to $14.78 billion-$15.06 billion vs $14.99 billion estimate.

S&P Global Widens FY2025 Adj EPS Guidance from $17.00-$17.25 to $16.75-$17.25 vs $17.01 Est; Lowers FY2025 Sales Guidance from $14.92B-$15.20B to $14.78B-$15.06B vs $14.99B Est

As of April 29, 2025, two stocks in the information technology sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Pony AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>)</h3>
<ul>
<li>Pony AI chief technology officer Lou Tiancheng told The Wall Street Journal that the company is getting closer to becoming profitable following a series of cost-cutting measures. Following the release of three new robotaxis at the Shanghai Auto Show last week, company executives reportedly said Pony AI can build its most advanced autonomous driving systems for 70% less than before. The company's stock jumped around 143% over the past five days and has a 52-week high of $23.88.</li>
<li>RSI Value: 71.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>PONY Price Action: Shares of Pony AI jumped 47.2% to close at $10.32 on Monday.</li>
<li>Edge Stock Ratings: 91.92 Momentum score with Value at 93.51. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/PONY"><img loading="lazy" decoding="async" width="477" height="186" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29065431/image-208.png" alt="" class="wp-image-892546" style="width:385px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29065431/image-208.png 477w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29065431/image-208-300x117.png 300w" sizes="(max-width: 477px) 100vw, 477px" /></a></figure>
<h3 class="wp-block-heading">Pegasystems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>)</h3>
<ul>
<li>On April 22, Pegasystems reported better-than-expected first-quarter financial results. &#8220;Pega GenAI has dramatically transformed how we engage with our clients,&#8221; said Alan Trefler, Pega founder and CEO. &#8220;Pega solutions and our approach to AI enables clients to accelerate progress in reaching their digital and legacy transformation goals.&#8221; The company's stock gained around 36% over the past five days and<a href="https://www.benzinga.com/quote/PEGA"> has a 52-week high</a> of $113.67.</li>
<li>RSI Value: 70.5</li>
<li>PEGA Price Action: Shares of Pegasystems fell 0.6% to close at $91.11 on Monday.</li>
</ul>
BZ Edge Rankings: Find out where other stocks stand—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">explore the full comparison now</a>. 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45060164/general-motors-coca-cola-and-3-stocks-to-watch-heading-into-tuesday">General Motors, Coca-Cola And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

PEGA

PONY

Top 2 Tech Stocks You May Want To Dump This Month

ASTE

Astec Enters Into Definitive Agreement to Acquire TerraSource Holdings For $245M; Anticipates Adj. EBITDA Multiple Of 5.9x Adjusted For Expected Tax Benefits Of ~$15M And Annual Run-Rate Synergies ~$10M By End Of Year Two

S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) reported quarterly earnings of $4.37 per share which beat the analyst consensus estimate of $4.19 by 4.3 percent. This is a 8.98 percent increase over earnings of $4.01 per share from the same period last year. The company reported quarterly sales of $3.78 billion which beat the analyst consensus estimate of $3.70 billion by 2.13 percent. This is a 8.19 percent increase over sales of $3.49 billion the same period last year.

S&P Global Q1 Adj. EPS $4.37 Beats $4.19 Estimate, Sales $3.78B Beat $3.70B Estimate

Findings from ALAMO Study Show AlloSure Lung is Associated with Prognosis of Chronic Lung Allograft Dysfunction and Restrictive Allograft Syndrome
AlloSure Lung Surveillance Monitoring Identifies the Onset of Acute Cellular Rejection and Treatment Response
CareDx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) – The Transplant Company&#x2122; – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx, together with study collaborators, presented new scientific evidence on the use of AlloSure&#xAE; Lung in clinical practice at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting &amp; Scientific Sessions, held from April 27-30 in Boston, Massachusetts.

CDNA

Caredx Presents New Scientific Evidence On Use Of Allosure Lung In Clinical Practice At ISHLT 45Th Annual Meeting & Scientific Sessions

General

Linde To Increase Its Supply Of Industrial Gases To Samsung In South Korea

H&amp;E Equipment Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEES#NASDAQ">HEES</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.63 by 95.24 percent. This is a 95.77 percent decrease over earnings of $0.71 per share from the same period last year. The company reported quarterly sales of $319.45 million which missed the analyst consensus estimate of $362.60 million by 11.90 percent. This is a 13.98 percent decrease over sales of $371.36 million the same period last year.

HEES

H&E Equipment Servs Q1 Adj. EPS $0.03 Misses $0.63 Estimate, Sales $319.45M Miss $362.60M Estimate

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the communication services sector.
<h3 class="wp-block-heading">Playtika Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTK#NASDAQ">PLTK</a>)</h3>
<ul>
<li>Dividend Yield: 7.65%</li>
<li>Morgan Stanley analyst Matthew Cost maintained an Equal-Weight rating and cut the price target from $7.25 to $5.75 on April 17, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Citigroup analyst Jason Bazinet maintained a Buy rating and lowered the price target from $10 to $9 on March 7, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: Playtika Holding will release financial results for the first quarter before the opening bell on Thursday, May 8.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0429">PLTK news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0429"><img loading="lazy" decoding="async" width="912" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29071054/image-209.png" alt="" class="wp-image-892557" style="width:550px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29071054/image-209.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29071054/image-209-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29071054/image-209-768x709.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">NetEase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>)</h3>
<ul>
<li>Dividend Yield: 2.46%</li>
<li>Barclays analyst Jiong Shao maintained an Equal-Weight rating and raised the price target from $82 to $104 on Feb. 24, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Benchmark analyst Fawne Jiang maintained a Buy rating and raised the price from $105 to $115 on Feb. 21, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On April 15, NetEase announced filing of annual report on Form 20-F for fiscal year 2024.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest NTES <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0429">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0429"><img loading="lazy" decoding="async" width="903" height="850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29071138/image-210.png" alt="" class="wp-image-892559" style="width:526px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29071138/image-210.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29071138/image-210-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29071138/image-210-768x723.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure>
<h3 class="wp-block-heading">AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>)</h3>
<ul>
<li>Dividend Yield: 4.07%</li>
<li>Barclays analyst Kanan Venkateshwar maintained an Overweight rating and raised the price target from $27 to $30 on April 25, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Morgan Stanley analyst Simon Flannery maintained an Overweight rating and raised the price target from $30 to $31 on April 24, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On April 23, the telecom giant reported quarterly operating revenues of $30.63 billion, up 2.0% year over year. This beat the analyst consensus estimate of $30.35 billion. Adjusted EPS of $0.51 also beat the analyst consensus estimate of $0.49.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0429">latest T news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0429"><img loading="lazy" decoding="async" width="907" height="815" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29071212/image-211.png" alt="" class="wp-image-892560" style="width:532px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29071212/image-211.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29071212/image-211-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29071212/image-211-768x690.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45060164/general-motors-coca-cola-and-3-stocks-to-watch-heading-into-tuesday">General Motors, Coca-Cola And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

NTES

PLTK

Wall Street's Most Accurate Analysts Weigh In On 3 Tech And Telcom Stocks Delivering High-Dividend Yields

Correction : Rosenblatt analyst Barton Crockett initiates coverage on Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) with a Buy rating and announces Price Target of $20.(Rating changed)

Comments

Datadog

Noticias

Últimas noticias sobre Datadog (NASDAQ:DDOG) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL